Hemostemix Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
HEM
- Investments
-
2
- Share Price
-
$0.02
- (As of Wednesday Closing)
Hemostemix General Information
Description
Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.
Contact Information
Website
www.hemostemix.comCorporate Office
- 707 Seventh Avenue South West
- Suite 1150
- Calgary, Alberta T2P 3H6
- Canada
Corporate Office
- 707 Seventh Avenue South West
- Suite 1150
- Calgary, Alberta T2P 3H6
- Canada
Hemostemix Timeline
Hemostemix Stock Performance
As of 18-Nov-2026, Hemostemix’s stock price is $0.02. Its current market cap is $5.17M with 211M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.08 | $5.17M | 211M | 57.7K | -$0.02 |
Hemostemix Financials Summary
As of 30-Jun-2026, Hemostemix has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 10,253 | 13,950 | 15,042 | 7,566 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,115) | (3,047) | (1,459) | (1,445) |
| Net Income | (3,286) | (3,371) | (1,908) | (1,853) |
| Total Assets | 181 | 618 | 691 | 237 |
| Total Debt | 2,508 | 2,630 | 3,440 | 3,258 |
Hemostemix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hemostemix Signals
Hemostemix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hemostemix Acquisitions (2)
Hemostemix’s most recent deal was a Merger/Acquisition with Hemostemix (Two Cardiology Practices). The deal was made on 03-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hemostemix (Two Cardiology Practices) | 03-Dec-2025 | Merger/Acquisition | Other Healthcare Services | ||
| Technical Ventures RX | 12-Nov-2014 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Hemostemix ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Hemostemix FAQs
-
When was Hemostemix founded?
Hemostemix was founded in 2003.
-
Where is Hemostemix headquartered?
Hemostemix is headquartered in Calgary, Canada.
-
What is the size of Hemostemix?
Hemostemix has 13 total employees.
-
What industry is Hemostemix in?
Hemostemix’s primary industry is Biotechnology.
-
Is Hemostemix a private or public company?
Hemostemix is a Public company.
-
What is Hemostemix’s stock symbol?
The ticker symbol for Hemostemix is HEM.
-
What is the current stock price of Hemostemix?
As of 18-Nov-2026 the stock price of Hemostemix is $0.02.
-
What is the current market cap of Hemostemix?
The current market capitalization of Hemostemix is $5.17M.
-
What is Hemostemix’s annual earnings per share (EPS)?
Hemostemix’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process